The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 24, 2025 for Docon Technologies ....
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Docon Technologies Private Limited, the promoter of Thyrocare Technologies, has released the pledge on 3,76,56,092 equity shares (representing 71.06% of Thyrocare's total share capital). The shares were earlier pledged with Vistra ITCL (India) Limited as Debenture Trustee against secured, unlisted, redeemable non-convertible debentures issued by API Holdings Limited (PAC), with a total outstanding redemption value of INR 1,820 crore (nominal value INR 1,545.38 crore). The debentures, held by Goldman Sachs India AIF Scheme I, Goldman Sachs India AIF Scheme II, and Evolution X Debt Capital Master Fund PTE Limited, have now been fully redeemed. This is a revised disclosure, with the original filed on September 18, 2025.
This is a positive development for shareholders as it removes a significant overhang on the stock — over 71% of Thyrocare's shares held by the promoter were pledged and are now fully unencumbered. The pledge release signals debt reduction at the promoter/PAC level (API Holdings) and removes forced-selling risk linked to debenture covenants.